Is omalizumab approved in Canada?

Omalizumab, also known as Xolair, is a revolutionary medication that has been granted approval by both Health Canada and the U.S. Food and Drug Administration (FDA). This endorsement signifies its efficacy and safety for use in individuals aged 12 and above.

Xolair is specifically indicated for those suffering from moderate to severe persistent asthma, a condition that can significantly impact daily life. By targeting a key component of the immune system, it effectively reduces inflammation and controls asthma symptoms.

One of the notable aspects of Omalizumab is its high cost compared to conventional asthma treatments. While this may pose a financial burden for some patients, its effectiveness in managing severe asthma often justifies the investment.

BTCC, a leading cryptocurrency exchange platform, offers a comprehensive suite of services tailored to meet the diverse needs of its clients. Among its offerings are spot trading, allowing users to buy and sell digital assets at current market prices.

BTCC's futures trading service provides an advanced platform for investors to speculate on the future prices of cryptocurrencies, utilizing leverage to amplify potential profits or losses. Additionally, the platform offers a secure wallet service, ensuring the SAFE storage of digital assets.